Streetbeat News

SOPH

SOPHiA GENETICS SA

https://www.sophiagenetics.com

Industry

Medical - Healthcare Information Services

SOPHiA GENETICS SA operates as a healthcare technology company. The company offers SOPHiA DDM platform, a cloud-based software-as-a-service platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, products, and services are used by hospital, laboratory, and biopharma worldwide. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Saint-Sulpice, Switzerland.

Open

3.27

Mkt cap

214M

Volume

21K

High

3.36

P/E Ratio

-3.01

52-wk high

7.37

Low

3.20

Div yield

N/A

52-wk low

2.70

SOPHiA GENETICS SA held its Q3 2024 earnings call, discussing company performance and leadership changes. Key participants included executives and analysts from major financial institutions.

Portfolio Pulse from

November 05, 2024 | 8:00 pm

SOPHiA GENETICS reported its Q3 2024 financial results, showing a slight revenue decline but improved cash burn and operating loss. The company experienced record analysis volume and reiterated its full-year guidance.

Portfolio Pulse from

November 05, 2024 | 12:30 pm

SOPHiA GENETICS has promoted Ross Muken to President and appointed George Cardoza as the new CFO, effective November 5, 2024.

Portfolio Pulse from

November 05, 2024 | 12:30 pm

SOPHiA GENETICS, in collaboration with AstraZeneca, is presenting AI-driven research at ESMO 2024. The study focuses on using machine learning to identify NSCLC patients who would benefit most from combination immunotherapy.